Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$5.41 USD
-0.03 (-0.55%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $5.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FATE 5.41 -0.03(-0.55%)
Will FATE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for FATE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FATE
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
FATE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
Novartis (NVS) to Report Q1 Earnings: What to Expect?
Other News for FATE
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics CFO Glenn Goddard to step down, Edward Dulac to succeed
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday